The Current Ratio as of November 2024 (TTM) for Basilea Pharmaceutica AG (BPMUF) is 4.10

According to Basilea Pharmaceutica AG’s latest financial reports and current stock price. The company's current Current Ratio is 4.10. This represents a change of 56.35% compared to the average of 2.62 of the last 4 quarters.

Basilea Pharmaceutica AG (BPMUF) Historical Current Ratio (quarterly & annually)

How has BPMUF Current Ratio performed in the past?

The mean historical Current Ratio of Basilea Pharmaceutica AG over the last ten years is 3.48. The current 4.10 Current Ratio has changed 11.67% with respect to the historical average. Over the past ten years (40 quarters), BPMUF's Current Ratio was at its highest in in the March 2021 quarter at 5.84. The Current Ratio was at its lowest in in the March 2024 quarter at 0.

Basilea Pharmaceutica AG (BPMUF) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Basilea Pharmaceutica AG Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Basilea Pharmaceutica AG (BPMUF) Average Current Ratio

How has BPMUF Current Ratio performed in the past?

The current Current Ratio of Basilea Pharmaceutica AG (BPMUF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Basilea Pharmaceutica AG (BPMUF) Current Ratio vs. Peers

How is BPMUF’s Current Ratio compared to its peers?

Basilea Pharmaceutica AG’s Current Ratio is less than Ocuphire Pharma, Inc. (10.68), greater than Reviva Pharmaceuticals Holdings, Inc. (0.41), greater than Protalix BioTherapeutics, Inc. (1.98), less than EyePoint Pharmaceuticals, Inc. (5.50), greater than SELLAS Life Sciences Group, Inc. (2.26), greater than ProQR Therapeutics N.V. (2.33), greater than Alnylam Pharmaceuticals, Inc. (2.75), greater than Wave Life Sciences Ltd. (1.90), greater than Blueprint Medicines Corporation (3.32), less than Apellis Pharmaceuticals, Inc. (4.36), less than Moderna, Inc. (0), less than CureVac N.V. (4.39), less than Novavax, Inc. (6.20), greater than CohBar, Inc. (0.93), less than Reata Pharmaceuticals, Inc. (15.69), less than BioNTech SE (6.75), less than Ginkgo Bioworks Holdings, Inc. (7.33), less than CRISPR Therapeutics AG (5.79), less than null (21.64),

Build a custom stock screener for Basilea Pharmaceutica AG (BPMUF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Basilea Pharmaceutica AG using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Basilea Pharmaceutica AG (BPMUF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Basilea Pharmaceutica AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.